Limits...
The Use of Fish Oil with Warfarin Does Not Significantly Affect either the International Normalised Ratio or Incidence of Adverse Events in Patients with Atrial Fibrillation and Deep Vein Thrombosis: A Retrospective Study

View Article: PubMed Central - PubMed

ABSTRACT

Background: Warfarin is a leading anticoagulant in the management of atrial fibrillation (AF) and deep vein thrombosis (DVT). Drug interactions influence the safety of warfarin use and while extensive literature exists regarding the effect on warfarin control and bleeding incidence with many medicines, there is little evidence on the influence of complementary medicines. The aim of this study was to assess the influence of fish and krill oil supplementation on warfarin control and bleeding incidence in AF and DVT patients. Methods: A retrospective analysis was conducted utilising patient information from a large private pathology clinic. AF and DVT patients receiving long-term warfarin therapy (>30 days) at the clinic and taking fish and krill oil supplements were eligible for study inclusion. Results: Of the 2081 patients assessed, a total of 573 warfarin users met the inclusion criteria with 145 patients in the fish and krill oil group (supplement group) and 428 patients in the control group. Overall, it was found that fish and krill oils did not significantly alter warfarin time in therapeutic range (TTR) or bleeding incidence, even when compared by gender. Conclusion: Omega-3 supplementation with fish and krill oil does not significantly affect long-term warfarin control and bleeding and thromboembolic events when consumed concurrently in patients managed at an anticoagulation clinic.

No MeSH data available.


Mean TITR for (A) fish oil versus no fish oil supplementation; and (B) gender comparison for fish oil versus no fish oil supplementation. Data is shown as mean and standard deviation; males (n = 316), females (n = 257).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5037562&req=5

nutrients-08-00578-f001: Mean TITR for (A) fish oil versus no fish oil supplementation; and (B) gender comparison for fish oil versus no fish oil supplementation. Data is shown as mean and standard deviation; males (n = 316), females (n = 257).

Mentions: Individual patient data was combined to calculate mean TTR, as shown in Figure 1. Overall, no significant difference was found between the mean TTR of supplement (86.7% ± 16.0%) and control patients (86.9% ± 10.2%), with both groups exceeding the recommended target TTR of 60% by approximately 25%. Additionally, no statistically significant difference was identified between the supplement and control groups in regard to minor bleeds per person-year with an incidence of 0.079 and 0.096, respectively (Table 2). There were no major bleeds recorded for either supplement or control groups. Furthermore, no thromboembolic events occurred in either group during the studied period.


The Use of Fish Oil with Warfarin Does Not Significantly Affect either the International Normalised Ratio or Incidence of Adverse Events in Patients with Atrial Fibrillation and Deep Vein Thrombosis: A Retrospective Study
Mean TITR for (A) fish oil versus no fish oil supplementation; and (B) gender comparison for fish oil versus no fish oil supplementation. Data is shown as mean and standard deviation; males (n = 316), females (n = 257).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5037562&req=5

nutrients-08-00578-f001: Mean TITR for (A) fish oil versus no fish oil supplementation; and (B) gender comparison for fish oil versus no fish oil supplementation. Data is shown as mean and standard deviation; males (n = 316), females (n = 257).
Mentions: Individual patient data was combined to calculate mean TTR, as shown in Figure 1. Overall, no significant difference was found between the mean TTR of supplement (86.7% ± 16.0%) and control patients (86.9% ± 10.2%), with both groups exceeding the recommended target TTR of 60% by approximately 25%. Additionally, no statistically significant difference was identified between the supplement and control groups in regard to minor bleeds per person-year with an incidence of 0.079 and 0.096, respectively (Table 2). There were no major bleeds recorded for either supplement or control groups. Furthermore, no thromboembolic events occurred in either group during the studied period.

View Article: PubMed Central - PubMed

ABSTRACT

Background: Warfarin is a leading anticoagulant in the management of atrial fibrillation (AF) and deep vein thrombosis (DVT). Drug interactions influence the safety of warfarin use and while extensive literature exists regarding the effect on warfarin control and bleeding incidence with many medicines, there is little evidence on the influence of complementary medicines. The aim of this study was to assess the influence of fish and krill oil supplementation on warfarin control and bleeding incidence in AF and DVT patients. Methods: A retrospective analysis was conducted utilising patient information from a large private pathology clinic. AF and DVT patients receiving long-term warfarin therapy (>30 days) at the clinic and taking fish and krill oil supplements were eligible for study inclusion. Results: Of the 2081 patients assessed, a total of 573 warfarin users met the inclusion criteria with 145 patients in the fish and krill oil group (supplement group) and 428 patients in the control group. Overall, it was found that fish and krill oils did not significantly alter warfarin time in therapeutic range (TTR) or bleeding incidence, even when compared by gender. Conclusion: Omega-3 supplementation with fish and krill oil does not significantly affect long-term warfarin control and bleeding and thromboembolic events when consumed concurrently in patients managed at an anticoagulation clinic.

No MeSH data available.